Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug;43(7):686-91.
doi: 10.1097/MCG.0b013e31818dd94c.

Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C

Kara W Chew  1 , Scott A Allen, Lynn E Taylor, Josiah D Rich, Edward Feller
Affiliations

Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C

Kara W Chew et al. J Clin Gastroenterol. 2009 Aug.

Erratum in

  • J Clin Gastroenterol. 2009 Nov-Dec;43(10):1010

Abstract

Goals: To report our experience with pegylated interferon and ribavirin treatment of hepatitis C virus (HCV) RNA-positive inmates at the Rhode Island Department of Corrections.

Background: An estimated 1 out of 3 HCV-infected individuals will spend time in a jail or prison within a 1-year period, making prisons a unique setting for management of chronic HCV.

Study: Chart review of all inmates identified as having initiated HCV treatment between October 2000 and April 2004. HCV-infected individuals were identified by HCV antibody screening at intake for known risk factors, elevated aminotransferase levels, or per individual request. Treatment followed standard guidelines with weight-based dosing of pegylated interferon-alpha2b and ribavirin. End points were completion of therapy plus 6 months for sustained virologic response (SVR), therapy discontinuation, and loss to follow-up.

Results: The cohort included 71 male patients, was mostly white (80%), and genotype 1 (65%). All 9 African Americans (AA) had genotype 1. Of 59 patients having liver biopsy, 41 had early stage disease. Overall SVR was 28%. Response rate was lower for genotype 1 compared with genotypes 2 and 3 (SVR 18% vs. 60% and 50%). Of inmates with genotype 1, no difference existed in treatment response by race (SVR 22% AA vs. 18% white). Thirty-three patients completed treatment, 26 stopped for side effects, and 5 for initial nonresponse. Eleven were lost to follow-up.

Conclusions: Acceptable HCV treatment outcomes can be achieved in prisons. Our small study indicates no difference in treatment response by AA versus white race for genotype 1.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Outcome in 71 male inmates treated for chronic hepatitis C at the Rhode Island Department of Corrections, 2000 to 2004.
FIGURE 2
FIGURE 2
Treatment response by genotype and race.
FIGURE 3
FIGURE 3
Treatment response by fibrosis stage.
See this image and copyright information in PMC

References

    1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562. - PubMed
    1. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate. American Association for the Study of Liver Diseases Annual Meeting; San Francisco, CA. November 2005; Abstract 44.
    1. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171. - PubMed
    1. Scientific Registry of Transplant Recipients Chapter VII. 2004 OPTN/SRTR Annual Report: Transplant Data 1993-2004. HHS/HRSA/SPB/DOT; UNOS; URREA.
    1. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36:S30–S34. - PubMed

Publication types

MeSH terms